Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Among other factors, sophistication of immunosuppressive (IS) regimen accounts for the remarkable success attained in the short- and medium-term solid organ transplant (SOT) survival. The use of steroids, mycophenolate mofetil and calcineurin inhibitors (CNI) have led to annual renal graft survival rates exceeding 90% in the last six decades. On the other hand, attrition rates of the allograft beyond the first year have remained unchanged. In addition, there is a persistent high cardiovascular (CV) mortality rate among transplant recipients with functioning grafts. These shortcomings are in part due to the metabolic effects of steroids, CNI and sirolimus (SRL), all of which are implicated in hypertension, new onset diabetes after transplant (NODAT), and dyslipidemia. In a bid to reduce the required amount of harmful maintenance agents, T-cell-depleting antibodies are increasingly used for induction therapy. The downsides to their use are greater incidence of opportunistic viral infections and malignancy. On the other hand, inadequate immunosuppression causes recurrent rejection episodes and therefore early-onset chronic allograft dysfunction. In addition to the adverse metabolic effects of the steroid rescue needed in these settings, the generated proinflammatory milieu may promote accelerated atherosclerotic disorders, thus setting up a vicious cycle. The recent availability of newer agent, belatacept holds a promise in reducing the incidence of metabolic disorders and hopefully its long-term CV consequences. Although therapeutic drug monitoring as applied to CNI may be helpful, pharmacodynamic tools are needed to promote a customized selection of IS agents that offer the most benefit to an individual without jeopardizing the allograft survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment with n-3 PUFAs 1 g o.d. may confer a small benefit in patients with chronic HF, as shown by a significant 9% relative risk reduction for mortality in the GISSI-HF RCT [475].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [475]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., Green, M. D., Jha, V., Josephson, M. A., Kiberd, B. A., et al. (2010) · Kidney International · doi:10.1038/ki.2009.377 · Cited by 1,735
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
Canalis, E., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,114
Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal
Lamb, K. E., Lodhi, S., & Meier-Kriesche, H.-U. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03283.x · Cited by 916
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Rapid Loss of Vertebral Mineral Density after Renal Transplantation
Julian, B. A., Laskow, D. A., Dubovsky, J., Dubovsky, E. V., Curtis, J. J., & Quarles, L. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108223250804 · Cited by 652 · cited 1×
“Observational study showed there was a positive correlation between cumulative steroid doses, accelerated cancellous bone remodeling, and loss of bone mineral density [Pichett et al. 1996; Julian et al. 1991].”
BackgroundWebster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., & Craig, J. C. (2005) · BMJ · doi:10.1136/bmj.38569.471007.ae · Cited by 587
Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Chapman, J. R., & Allen, R. D. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128636.70499.6e · Cited by 498
Research works printed but not linked: 12
- 10.1186/2047144021 · doi:10.1186/2047144021
- Einollahi B., 2014, J Nephropathol, 3, 139
- Juan Khong M., 2014, Neth J Med, 72, 127
- Masson P., 2014, Cochrane Database Syst Rev, 11, CD010699
- Pascual J., 2009, Cochrane Database Syst Rev, 4, CD007669
- Pourmand G., 2015, Acta Med Iran, 53, 297
- Razeghi E., 2011, Exp Clin Transplant, 9, 230
- Taber D., 2013, Ethn Dis, 23, 238
- Turgay M., 2012, Bratisl Lek Listy, 113, 10
- Webster A., 2010, Cochrane Database Syst Rev, 1, CD003897
- Webster A., 2005, Cochrane Database Syst Rev, 4, CD003961
- Wjidan K., 2015, J Clin Diagn Res, 9, OF06
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“These effects vary with different immunosuppressive drugs.(497,498,502) 506 The management of dyslipidaemias in transplant recipients is comparable to what is recommended for patients at high or very high ASCVD risk, although more attention is needed regarding the causes of the lipid disturbances and possible side eff…”
Esterline, R. L., Vaag, A., Oscarsson, J., & Vora, J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 98
Metz, D., Holford, N. H. G., Kausman, J., Walker, A., Cranswick, N., Staatz, C. E., Barraclough, K. A., & Ierino, F. L. (2019) · Transplantation · doi:10.1097/tp.0000000000002762 · Cited by 80
Metabolic Consequences of Solid Organ Transplantation
Bhat, M., Usmani, S. E., Azhie, A., & Woo, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa030 · Cited by 80
Metadata
- Authors
- Bamgbola, O.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Bamgbola, Oluwatoyin
- ORCID
- Bamgbola, Oluwatoyin
- Venue
- Therapeutic Advances in Endocrinology and Metabolism
- Publisher
- SAGE Publications
- Published
- 2016-03-30
- Volume
- 7
- Issue
- 3
- Pages
- 110-127
- ISSN
- 2042-0188 (ISSN-L)
- 2042-0196
- PMC
- PMC4892400
- OpenAlex
- W2320017047
- Cited by
- 85
- References
- 141
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 7 · 2023: 2 · 2022: 12 · 2021: 12 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 11 · 2016: 3
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Endocrinology and Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Keywords
- immunosuppressants, solid organ transplantation, metabolic complications, calcineurin inhibitors, rapamycin, corticosteroids, mycophenolate mofetil, post-transplant diabetes mellitus, hypertension, dyslipidemia, cardiovascular mortality, belatacept, chronic allograft dysfunction, atherosclerosis, therapeutic drug monitoring, personalized immunosuppression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. https://app.cochat.ai/papers/10.1177/2042018816641580
- The paper
- Bamgbola, O. (2016). Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Therapeutic Advances in Endocrinology and Metabolism. https://doi.org/10.1177/2042018816641580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.